JP2014530246A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530246A5 JP2014530246A5 JP2014536225A JP2014536225A JP2014530246A5 JP 2014530246 A5 JP2014530246 A5 JP 2014530246A5 JP 2014536225 A JP2014536225 A JP 2014536225A JP 2014536225 A JP2014536225 A JP 2014536225A JP 2014530246 A5 JP2014530246 A5 JP 2014530246A5
- Authority
- JP
- Japan
- Prior art keywords
- factor viii
- sulfated glycosaminoglycan
- administered
- dose
- sulfated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010054218 Factor VIII Proteins 0.000 claims 23
- 102000001690 Factor VIII Human genes 0.000 claims 23
- 229960000301 factor viii Drugs 0.000 claims 23
- 229920002683 Glycosaminoglycan Polymers 0.000 claims 21
- 230000037396 body weight Effects 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 4
- 208000031169 hemorrhagic disease Diseases 0.000 claims 4
- 229920000669 heparin Polymers 0.000 claims 4
- 229960002897 heparin Drugs 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 238000010253 intravenous injection Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 1
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 108010047303 von Willebrand Factor Proteins 0.000 claims 1
- 102100036537 von Willebrand factor Human genes 0.000 claims 1
- 229960001134 von willebrand factor Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161548606P | 2011-10-18 | 2011-10-18 | |
| US61/548,606 | 2011-10-18 | ||
| EP11185648.0 | 2011-10-18 | ||
| EP11185648 | 2011-10-18 | ||
| PCT/EP2012/070615 WO2013057167A1 (en) | 2011-10-18 | 2012-10-18 | Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014530246A JP2014530246A (ja) | 2014-11-17 |
| JP2014530246A5 true JP2014530246A5 (cg-RX-API-DMAC7.html) | 2015-11-26 |
| JP6072810B2 JP6072810B2 (ja) | 2017-02-01 |
Family
ID=48140372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014536225A Expired - Fee Related JP6072810B2 (ja) | 2011-10-18 | 2012-10-18 | 第ｖｉｉｉ因子の生物学的利用能を改善するための硫酸化グリコサミノグリカンの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9393289B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2768522B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6072810B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20140083036A (cg-RX-API-DMAC7.html) |
| CN (1) | CN103889445A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012318279B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2852397A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2768522T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2600081T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013057167A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2768521B1 (en) | 2011-10-18 | 2016-07-13 | CSL Behring GmbH | Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor viii |
| BR112016026842A2 (pt) | 2014-06-06 | 2017-12-12 | Octapharma Ag | preparação compreendendo fator viii e peptídeos de fator de von willebrand |
| CA2960282C (en) * | 2014-09-12 | 2025-09-09 | The Regents Of The University Of California | Human anti-CD46 macropinosome-forming antibodies and target anti-cancer therapeutic agents |
| CN114106146B (zh) * | 2015-02-06 | 2025-05-06 | 北卡罗来纳大学查珀尔希尔分校 | 优化的人类凝血因子viii基因表达盒及其用途 |
| SE539575C2 (en) * | 2015-07-30 | 2017-10-17 | Tx Medic Ab | Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| EP0218712B1 (en) | 1985-04-12 | 1992-02-26 | Genetics Institute, Inc. | Novel procoagulant proteins |
| FR2673632A1 (fr) | 1991-03-08 | 1992-09-11 | Lille Transfusion Sanguine | Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique. |
| SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
| IL113010A0 (en) * | 1994-03-31 | 1995-10-31 | Pharmacia Ab | Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
| DE4435485C1 (de) | 1994-10-04 | 1996-03-21 | Immuno Ag | Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor |
| JP3987114B2 (ja) | 1996-04-24 | 2007-10-03 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン | 不活性化耐性第▲８▼因子 |
| WO2000024759A1 (en) | 1998-10-23 | 2000-05-04 | The Trustees Of The University Of Pennsylvania | Systemic delivery of gene products via skin |
| CA2450125A1 (en) | 2001-06-15 | 2002-12-27 | Andre C. Schuh | Gene therapy for hemophilia a |
| US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
| ES2558102T3 (es) | 2003-05-06 | 2016-02-02 | Biogen Hemophilia Inc. | Proteínas quiméricas del factor de coagulación para el tratamiento de un trastorno hemostático |
| WO2009062100A1 (en) * | 2007-11-09 | 2009-05-14 | Baxter International Inc. | Modified recombinant factor viii and von willebrand factor and methods of use |
| EP2626080A3 (en) * | 2008-02-27 | 2014-03-05 | Novo Nordisk A/S | Conjugated factor VIII molecules |
| KR20120061898A (ko) * | 2009-08-20 | 2012-06-13 | 체에스엘 베링 게엠베하 | 출혈성 장애의 치료요법 및 예방 치료에 있어서의 비정맥내 투여를 위한 알부민 융합 응고 인자 |
| WO2011095604A1 (en) * | 2010-02-04 | 2011-08-11 | Octapharma Biopharmaceuticals Gmbh | Half-life prolongation of proteins |
-
2012
- 2012-10-18 DK DK12777895.9T patent/DK2768522T3/en active
- 2012-10-18 AU AU2012318279A patent/AU2012318279B2/en not_active Ceased
- 2012-10-18 US US14/352,540 patent/US9393289B2/en not_active Expired - Fee Related
- 2012-10-18 EP EP12777895.9A patent/EP2768522B1/en not_active Not-in-force
- 2012-10-18 ES ES12777895.9T patent/ES2600081T3/es active Active
- 2012-10-18 JP JP2014536225A patent/JP6072810B2/ja not_active Expired - Fee Related
- 2012-10-18 CN CN201280051236.7A patent/CN103889445A/zh active Pending
- 2012-10-18 WO PCT/EP2012/070615 patent/WO2013057167A1/en not_active Ceased
- 2012-10-18 CA CA2852397A patent/CA2852397A1/en not_active Abandoned
- 2012-10-18 KR KR1020147013300A patent/KR20140083036A/ko not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021050953A8 (en) | Compositions and methods for the delivery of therapeutic biologics for treatment of disease | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| AR082150A1 (es) | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolin-3-carboxamida deuterada, sales y usos de la misma, metodo de tratamiento, mezcla compuestos, composicion farmaceutica, proceso de preparacion, compuesto enriquecido con deuterio | |
| MX2022007012A (es) | Uso de un agonista doble del receptor de glp-1/glucagon de larga accion para el tratamiento de la enfermedad de higado graso no alcoholico. | |
| EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
| JP2016517421A5 (cg-RX-API-DMAC7.html) | ||
| MX2017004592A (es) | Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos. | |
| NZ747657A (en) | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative | |
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| RU2015116264A (ru) | Композиции и способы лечения сердечной недостаточности у пациентов с диабетом | |
| JP2014530246A5 (cg-RX-API-DMAC7.html) | ||
| MX350582B (es) | Tratamiento de trastornos de la coagulacion mediante la administracion del factor de von willebrand (vwf) recombinante. | |
| JP2014530873A5 (cg-RX-API-DMAC7.html) | ||
| JP2015532293A5 (ja) | 糖尿病患者における心不全の治療用組成物 | |
| PH12015501373A1 (en) | Injectable depot formulation comprising optically active tolvaptan and process of producing the same | |
| PH12015502465A1 (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
| RU2013108390A (ru) | Фармацевтическая композиция для предотвращения периоперационной артериальной гипотензии у человека | |
| JP2013520447A5 (cg-RX-API-DMAC7.html) | ||
| FI3648788T5 (fi) | Maha-suolikanavan verenvuodon hoito vaikeaa von willebrandin tautia sairastavilla potilailla antamalla rekombinanttia vwf:ää | |
| FI3590960T3 (fi) | Perifeeristen hermojen IgG-stimuloitu remyelinaatio | |
| WO2019094823A8 (en) | Mitochondrial localization signals in human tafazzin and uses thereof | |
| WO2014145199A8 (en) | Retrograde delivery of sdf-1 for treatment of myocardial infarction | |
| MY163107A (en) | Pharmaceutical composition for the treatment of bladder disorders | |
| Marzuillo et al. | Ondasetron Is More Likely Than Ketamine to Cause Ventricular Tachycardia | |
| AT511582B1 (de) | Verwendung von keyhole-limpet-hämocyanin oder spaltprodukten davon |